XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million

Reuters03-18

XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million

XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda. FY 2025 net income was USD 31.71 million, and net cash provided by operating activities was USD 2.87 million. For FY 2025, XOMA Royalty reported USD 50.5 million of cash receipts, including USD 33.6 million in royalties and commercial payments and USD 16.9 million in milestones, with total receipts up 9% and royalties up 68%. Owen Hughes said the company achieved positive operating cash flow in 2025 and highlighted 2026 catalysts including volixibat Phase 2b data in PSC in Q2 and ersodetug Phase 3 data in tumor HI in 2H.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180600PRIMZONEFULLFEED9674143) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620623175?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620623175","market":"us","top_or_hot":-1,"title":"XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda. FY 2025 net income was USD 31.71 million, and net cash provided by operating activities was USD 2.87 million. For FY 2025, XOMA Royalty reported USD 50.5 million of cash receipts, including USD 33.6 million in royalties and commercial payments and USD 16.9 million in milestones, with total receipts up 9% and royalties up 68%. Owen Hughes said the company achieved positive operating cash flow in 2025 and highlighted 2026 catalysts including volixibat Phase 2b data in PSC in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> and ersodetug Phase 3 data in tumor HI in 2H.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180600PRIMZONEFULLFEED9674143) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda. FY 2025 net income was USD 31.71 million, and net cash provided by operating activities was USD 2.87 million. For FY 2025, XOMA Royalty reported USD 50.5 million of cash receipts, including USD 33.6 million in royalties and commercial payments and USD 16.9 million in milestones, with total receipts up 9% and royalties up 68%. Owen Hughes said the company achieved positive operating cash flow in 2025 and highlighted 2026 catalysts including volixibat Phase 2b data in PSC in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> and ersodetug Phase 3 data in tumor HI in 2H.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180600PRIMZONEFULLFEED9674143) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL63mXy9:1","article_id":"2620623175","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620623175","pubTimestamp":1773828079,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda. FY 2025 net income was USD 31.71 million, and net cash provided by operating activities was USD 2.87 million. For FY 2025, XOMA Royalty reported USD 50.5 million of cash receipts, including USD 33.6 million in royalties and commercial payments and USD 16.9 million in milestones, with total receipts up 9% and royalties up 68%. Owen Hughes said the company achieved positive operating cash flow in 2025 and highlighted 2026 catalysts including volixibat Phase 2b data in PSC in Q2 and ersodetug Phase 3 data in tumor HI in 2H.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","RZLT":"Rezolute, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4139":"生物科技","XOMA":"标记临床研究","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Xoma Royal 2025财年收入增长83%至5215万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XOMA":0.9,"RZLT":0.9,"NDAQ":0.9},"content_text":"XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million\n    \n\n        XOMA Royalty published a press release reporting Q4 and full-year 2025 financial results. FY 2025 income and revenues rose 83% to USD 52.15 million, driven primarily by higher income related to VABYSMO and OJEMDA and milestone payments from Rezolute and Takeda. FY 2025 net income was USD 31.71 million, and net cash provided by operating activities was USD 2.87 million. For FY 2025, XOMA Royalty reported USD 50.5 million of cash receipts, including USD 33.6 million in royalties and commercial payments and USD 16.9 million in milestones, with total receipts up 9% and royalties up 68%. Owen Hughes said the company achieved positive operating cash flow in 2025 and highlighted 2026 catalysts including volixibat Phase 2b data in PSC in Q2 and ersodetug Phase 3 data in tumor HI in 2H.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180600PRIMZONEFULLFEED9674143) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620623175","isCrawlerRequest":true}